Evidence map›Paper›PMID 33945286›Full record

ArticleJournal of medicinal chemistry2021

Highly Efficient Activatable MRI Probe to Sense Myeloperoxidase Activity.

Cuihua Wang, David Cheng, Negin Jalali Motlagh, Enrico G Kuellenberg, Gregory R Wojtkiewicz, Stephen P Schmidt, Roland Stocker, John W Chen

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. An HRedox biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Cuihua WangInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States.ORCID 0000-0003-3417-6947
David ChengVictor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia.
Negin Jalali MotlaghInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States.
Enrico G KuellenbergInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States.
Gregory R WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
Stephen P SchmidtCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
Roland StockerVictor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia.
John W ChenInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States.
Harvard University · USVictor Chang Cardiac Research Institute · AU

Funding

Imaging macrophage and microglial functional diversity in strokeR01NS103998 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JOHN W · 2018 to 2022
$2.6M
Tracking M2-Like Macrophages in Cardiopulmonary Diseases by Magnetic Resonance ImagingK25HL150305 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, CUIHUA · 2020 to 2024
$763k
NHLBI NIH HHS K25 HL150305NINDS NIH HHS R01 NS103998
6 · The paper itself

Abstract

Myeloperoxidase (MPO) is a key component of innate immunity but can damage tissues when secreted abnormally. We developed a new generation of a highly efficient MPO-activatable MRI probe (heMAMP) to report MPO activity. heMAMP has improved Gd stability compared to bis-5-HT-Gd-DTPA (MPO-Gd) and demonstrates no significant cytotoxicity. Importantly, heMAMP is more efficiently activated by MPO compared to MPO-Gd, 5HT-DOTA(Gd), and 5HT-DOTAGA-Gd. Molecular docking simulations revealed that heMAMP has increased rigidity via hydrogen bonding intramolecularly and improved binding affinity to the active site of MPO. In animals with subcutaneous inflammation, activated heMAMP showed a 2-3-fold increased contrast-to-noise ratio (CNR) compared to activated MPO-Gd and 4-10 times higher CNR compared to conventional DOTA-Gd. This increased efficacy was further confirmed in a model of unstable atherosclerotic plaque where heMAMP demonstrated a comparable signal increase and responsiveness to MPO inhibition at a 3-fold lower dosage compared to MPO-Gd, further underscoring heMAMP as a potential translational candidate.

Indexed as

Magnetic Resonance ImagingAnimalsAtherosclerosisBinding SitesCalciumCatalytic DomainCell SurvivalContrast MediaDisease Models, AnimalDrug DesignFemaleGadolinium DTPAHalf-LifeMiceMice, Inbred BALB CPeroxidaseCalciumContrast MediaGadolinium DTPAPeroxidaseZinc

Identifiers

PMID33945286
PMCPMC8564765
OpenAlexW3157906258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.